



Pharmacy & Therapeutics Committee

Meeting Minutes

Thursday, November 16, 2023

7:00 a.m. to 8:45 a.m.

Video Call: <https://meet.google.com/tni-wias-qke>

Committee Members Present:

Cole Sloan, PharmD
Bryan Larson, PharmD
Michelle Hoffmann, MD
Rocky Parker, PharmD
Susan Siegfried, MD

Committee Members Excused:

Clayton Grace, PharmD

Dept. of Health/Div. of Health Care Financing Staff Present:

Luis Moreno, PharmD, CDCES
Ngan Huynh, PharmD
Stephanie Byrne, PharmD
Lisa Angelos, PharmD, BCSCP, CAPP
Yoon Kim-Butterfield, MD

University of Utah Drug Regimen Review Center Staff Presenter:

Monet Luloh, PharmD

Other Individuals Present:

Aimee Redhair, Biogen	Lauren Heath, UofU DRRC
Bob, Healthy U	Lisa Pulver, J&J
Camille Kerr, Regeneron	Lynda Finch, Biogen
Dana Mennen, Apellis	Matthew Call, UofU
Gary Parenteau, Dexcom	Money Luloh, UofU DRRC
Heidi Goodrich, Molina	Todd Estus, Regeneron
Jason Bott, Lilly	
Jason Smith	

Pharmacy & Therapeutics Committee

Meeting Minutes

Meeting conducted by: Cole Sloan

1. **Welcome & Housekeeping:** Cole Sloan opened the meeting and announced a quorum.

Cole Sloan introduced the newest P&T committee member, Rocky Parker, PharmD. Rocky shared his pharmacy experience and expressed appreciation for being included on the Utah Medicaid P&T Board. Bryan Larson welcomed Rocky Parker and expressed his appreciation for Rocky's willingness to serve.

Bryan Larson explained how the P&T Board operates to ensure Rocky Parker's understanding.

2. **Review and Approval of September Minutes:** Cole Sloan made a motion to approve the minutes from September. Susan Siegfried seconded the motion. All in favor, motion passed. Rocky Parker abstained.
3. **Drug Utilization Review (DUR) Board update:** The DUR board met in October to discuss Sickle Cell Disease. November DUR Board Meeting was canceled. December DUR Board Meeting will focus on antidepressant use in children.
4. **Topic: Intravitreal Anti-Vascular Endothelial Growth Factors**
 - a. Monet Luloh, PharmD from the University of Utah presented on Intravitreal Anti-Vascular Endothelial Growth Factors
 - b. PDL considerations based on findings:
 1. At least 1 FDA-approved injectable (ie, non-implant) intravitreal anti-VEGF agent to be PDL-preferred
 1. Off-label use of intravitreal bevacizumab can be an acceptable alternative to PDL-preferred, FDA-approved intravitreal anti-VEGF agents, accessible by prior authorization
 1. Has recognized off-label uses for nAMD, DME, DR, ME-RVO, mCNV, and ROP in Micromedex, each rated as Evidence Favors Efficacy

Pharmacy & Therapeutics Committee

Meeting Minutes

2. Bevacizumab must be compounded for intravitreal use
 2. Ocular implant of ranibizumab may be reserved for patients who have limitations using other agents
 1. Approved only for nAMD in patients who have previously responded to ≥ 2 anti-VEGF intravitreal injections
5. **Public Comment:**
 - a. Lynda Finch, Biogen. Presented on Byooviz (ranibizumab-nuna injection for intravitreal use)
 - b. Todd Estus, Regeneron. Presented on Eylea HD (afibercept)
6. **Committee Discussion:**

Cole Sloan mentioned he didn't think we should look at these products by individual indications. Bryan Larson agreed and mentioned we have 3 reviews scheduled; this particular review is focused on ocular products.

Cole Sloan motioned:

 - a. At least 1 FDA injectable, clarifying that it is non-implant, intravitreal anti-VEGF agent be included on the PDL as preferred.
Bryan seconded. All in favor, motion passed.
 - b. Cole Sloan asked if there was a need to discuss the prior authorization and Bryan Larson responded that prior authorization discussions occur with the DUR Board.
 - c. Cole Sloan asked if there is a need for a grandfathering clause. Bryan Larson responded that because it is already going through a prior authorization process and having good results with it, the product would continue to be covered. So in this case, a grandfathering clause is not necessary.
 - d. Cole Sloan asked if there were any further items for discussion; none were brought forth.

Pharmacy & Therapeutics Committee

Meeting Minutes

7. **Public Meeting Adjourned:** Cole Sloan motioned to close the meeting. Bryan Larson seconded the motion. Unanimous Approval.
8. **Next meeting is scheduled for** February 15, 2024 to further discuss Anti-VEGF IV/oral products.

Audio recording of all P&T meetings are available online at:

https://www.youtube.com/playlist?list=PLDnbxUh8egJ-NQgDbOJ_kkYo_zmrmwixf